Nxera Pharma Co., Ltd.
Received $1.8 Million Milestone from Centessa
Nexera Pharma Inc. received $1.8 million (approximately JPY 281 million) as a milestone payment from Centessa for the development drug targeting neuropsychiatric disorders, scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.
Key Figures
- Milestone Amount Received: $1.8 million (approximately JPY 281 million)
- Scheduled Revenue Recognition: Q1 of fiscal year ending December 2026
- Exchange Rate: 1 USD = JPY 156.10 (as of 2026-02-11)
AI要約
Regarding Milestone Receipt from Partner
Nexera Pharma Inc. has received $1.8 million (approximately JPY 281 million) from its partner Centessa Pharmaceuticals Limited as a milestone payment during the early development phase of ORX489, an orexin receptor 2 (OX2R) agonist targeting neuropsychiatric disorders. This amount is scheduled to be recorded as revenue in the first quarter of the fiscal year ending December 2026.
Overview of Nexera Pharma's Business
Nexera Pharma Inc. is a technology-based biopharmaceutical company with multiple marketed products and a pipeline of over 30 molecules primarily in Japan and the APAC region. The company focuses on growth areas including obesity and metabolic disorders, neurological and neuropsychiatric conditions, as well as immune and inflammatory diseases, conducting global business operations.
